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There has been continuous development in the ﬁeld of health technology assessment (HTA) owing to the added value of HTA
in supporting healthcare reimbursement decisions. Collaboration and engagement among countries in Asia has been carried
out to share experiences and learning on the barriers and factors facilitating the implementation and use of HTA in policy
making. A symposium on the topic of Health Technology Assessment (HTA): Selecting the Highest Value Carewas held on January
10, 2019 at the National University of Singapore, during which 3 major challenges confronting HTA development in Asia were
identiﬁed. The symposium also offered possible ways to overcome the challenges.
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On January 10, 2019, a symposium on the topic of Health
Technology Assessment (HTA): Selecting the Highest Value Care
was held at the National University of Singapore (NUS).1
There were approximately 300 participants from more than
10 countries, including Ghana, India, Indonesia, Malaysia, the
Philippines, Singapore, and Thailand, in addition to the Hong
Kong Special Administrative Region of the People’s Republic
of China. Speakers included the chair of the Subcommittee of
the National List of Essential Medicines in Thailand and the
HTA Committee in Indonesia in addition to academics and
representatives from global partners such as the Interna-
tional Decision Initiative (iDSI) and the World Health
Organization.
Asia is viewed as a region where interest and capacity in HTA
has signiﬁcantly improved over a short period. Nevertheless, the
countries that have implemented HTA are at various levels of
economic development and stages of implementing public health
insurance schemes. During the symposium, important issues on
the role of HTA in healthcare were discussed and common char-
acteristics and different points of view across countries were
observed. In this article, the authors would like to highlight 3
challenges that emerged during the symposium: (1) the increasingss correspondence to: Waranya Rattanavipapong, MSc, Department of Heal
buri 11000, Thailand. Email: waranya.r@hitap.net
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doi.org/10.1016/j.vhri.2019.07.001need and demand for health priority setting in this region, (2) the
lack of infrastructure and technical capacity to cope with the
increasing demand, and (3) the inadequate involvement of
stakeholders in the HTA process. We then propose the way for-
ward for HTA in the region.Need and Demand for HTA
Research suggests that the increase in healthcare spending is
due to economic development, adoption of high-cost technolo-
gies, an aging population, and rapid uptake of universal health
coverage (UHC).2-4 This movement, in turn, has led to an increase
in the demand for priority setting using HTA. Although these
trends are sometimes presented as problems, this symposium
takes a different view and highlights that these are, in fact, the
byproducts of our success in the spheres of social and economic
development in recent decades. These complex problems exist,
and HTA represents an approach to support complex decision
making, for example, to better inform decision makers to make
tradeoffs in resource allocation.
The advancement in science and technology has made more
health technologies available in the market. This trend poses a
challenge not only to the government or payer who needs toth, Ministry of Public Health, 6th Floor, 6th Building, Tiwanon Rd, Muang,
half of ISPOR–The professional society for health economics and outcomes
mons.org/licenses/by/4.0/).
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-- 67decide whether a new technology is to be added in the UHC
beneﬁts package, but also to health professionals who want to
adopt the best clinical practice and to the patients who may
recognize that better treatment is available but not accessible.
Second, people are now living healthier and longer lives, which
results in a greater demand for health services. Lastly, good
governance has become more established in health systems, and
that has promoted the use of evidence-informed policy
decisions.
To respond to the aforementioned challenges, many countries
in the Asian region use HTA for priority setting, although the mode
of implementation depends on the health system design and local
social values. For example, in India, state governments play a
major role in implementing healthcare policies, and the private
sector is a signiﬁcant provider of services and households bear a
high proportion of healthcare costs. Meanwhile, Thailand has a
centralized system with a high proportion of government
spending on healthcare. Indonesia presents a different case where
there is a focus on the devolution of decision making to local
governments. In Singapore, there is an emphasis on personal re-
sponsibility, where individuals are expected to contribute to the
cost of healthcare. These examples reﬂect the heterogeneity in the
healthcare systems in the region and the challenge of tailoring
HTA in a way that is responsive to local circumstances. The dif-
ference calls for governments or payers to design a mechanism for
using HTA for healthcare decision making that is relevant to the
contextual factors, and for HTA agencies to identify the role and
opportunities to provide the highest value for the system.HTA Infrastructure
Representatives from most countries at the symposium
expressed concern about the lack of infrastructure for HTA, such
as reliable cost databases and local health outcomes data to
estimate quality-adjusted life years. Further, there is a lack of
technical capacity, especially in the ﬁeld of health economics
and disease modelling, and the increased need and demand for
HTA exacerbates the gap between demand and supply for HTA
technical capacity. The Health Intervention and Technology
Assessment Program (HITAP) has conducted annual training for
local scholars for the past 15 years, but that alone is not enough
to meet demand in the region. The NUS is now trying to bridge
this gap in the region by developing an annual course on HTA to
supplement local training in countries through the newly
established Center for Health Intervention and Policy Evaluation
Research. Nevertheless, the question remains of how such ini-
tiatives can be scaled up. Suggestions from the symposium
called for making greater efforts to strengthen HTA capacity
through regional and global collaborations such as HTAsiaLink,5
and building on the existing work under iDSI, such as the iDSI
Reference Case6 and the Guide to Economic Analysis and
Research. The Guide to Economic Analysis and Research, an
online resource funded by iDSI, shows that there are 43 HTA
guidelines available worldwide, yet only 3 are in low- and
middle-income countries.7 If all countries were to have their
own guidelines, this would mean developing more than 100
new guidelines. The authors believe that this need not be the
way forward and the investment could be more efﬁciently
applied, if countries learn from one another on these infra-
structural and technical aspects without having to reinvent the
wheel.
During the last decade, academics and HTA practitioners have
paid more attention to the generalizability and transferability of
methodological aspects of HTA and its results.8-11 In this decade,the HTA community ought to pay at least equal attention to the
generalizability and transferability of HTA applications. This would
allow meaningful conclusions on why and how HTA is being used
in different countries. For example, in Thailand, HTA is used for
assessing new technologies that are to be introduced to the ben-
eﬁts package, whereas in Singapore, HTA is being used to make
subsidy decisions for existing technologies. In India, HTA is being
used to develop a beneﬁts package for its UHC program, whereas
Indonesia is using HTA to delist less cost-effective medicines and
interventions from its beneﬁts package. Better understanding of
how HTA is used in practice will provide a stronger foundation for
performance comparison and benchmarking of HTA by tracking
the progress of HTA systems in each country, as well as systematic
information sharing and collaboration on technical studies
through, for example, joint HTAs for interventions and maintain-
ing repositories of existing relevant models that are of common
interest.Stakeholders
There was consensus at the symposium that not only technical
capacity but also the institutional arrangements are critical to
ensuring a credible process for incorporating evidence into policy
with transparency and participation as core principles. This is
where the role of stakeholders becomes signiﬁcant. There was
wide-ranging discussion of the question of whether the current
practice is sufﬁcient for identifying impactful topics for HTA
through stakeholder participation and how to ensure that as-
sessments are not driven by supply but rather by need and de-
mand. In particular, the role of different stakeholders, for example,
private sector and civil society, may differ at different stages of
HTA development.
The authors propose the following way to take HTA forward in
Asia. It was agreed that enhancing the understanding of HTA
among various groups of stakeholders and augmenting their
involvement will be crucial in the coming years. The creation of
the National Institute for Health and Care Excellence and HITAP
brought these issues in the public realm and allowed stakeholders
to debate on health policies.12,13 For example, when the National
Institute for Health and Care Excellence says no to including
medicines, or when HITAP advises against inclusion of new
68 VALUE IN HEALTH REGIONAL ISSUES - 2020technologies, it provokes debate about these issues among health
professionals, decision makers, and media and sensitizes the
public about the rationale for rationing by decision makers.
Furthermore, there are several communication methods HTA
agencies can implement, such as inviting relevant stakeholders to
participate in consultation meetings in the HTA process to facili-
tate direct interaction, or setting up webpages dedicated to
disseminating HTA results.
Based on the discussion during the symposium, the authors
believe that it is the responsibility of HTA agencies to better
communicate the use of HTA and its societal beneﬁts.Conclusion
Table 1 summarizes the recommendations that address the
main challenges. The HTA symposium in Singapore has ended, but
the earlier discussion forebodes the beginning of a new chapter of
HTA for Asia. The authors expect that successfully addressing the 3
challenges will inform the future directions of HTA in the region
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